Biom’up Expands Management Team
2.9.2020 14:00:00 EEST | Business Wire | Press release
Biom’up France SAS and its affiliates (together, “Biom’up”), a leading developer of hemostatic products used in the surgical channel, currently featuring HEMOBLAST™ Bellows, today announced the appointment of Stéphanie Boileau-Canu as Chief Financial Officer and Emmanuel Zylber as Chief Scientific Officer. Ms. Boileau-Canu and Mr. Zylber will serve on the Company’s executive committee, reporting directly to Biom’up Group CEO, Patrice Ferrand.
Ms. Boileau-Canu brings deep financial expertise, gained across more than two decades in a diverse array of executive finance positions, including with SEB Group and several privately held companies. Mr. Zylber is a well-regarded technology and innovation executive, with vast R&D and product development experience, particularly within the medical device space.
Patrice Ferrand, Group CEO of Biom’up, said, “We are most pleased to welcome Stéphanie and Emmanuel to our management team at this very exciting time in our company’s evolution. Stéphanie and Emmanuel bring deep and complementary skills that will empower Biom’up to further expand upon our position in the highly valued hemostat market. We look forward to updating the medical community on a host of exciting near-term milestones, including clinical developments and geographic expansion.”
Additional Biographic Information
In nearly two decades at SEB Group, Ms. Boileau-Canu worked across several continents, in various finance-oriented leadership positions. During her career, she has also served a number of family-owned SMEs, first at Everial and then at Implid. Ms. Boileau-Canu received undergraduate and master’s degrees from IAE Dijon and an MBA from Emylon Business School.
Mr. Zylber is a proven and well-respected R&D leader. He has vast experience in product development and registration in the medical device industry, particularly the fields of spine/orthopedics, single-use medical and surgical products. With an entrepreneurial spirit, Mr. Zylber has worked at large, global companies such as Zimmer and Vygon, and private investment backed organizations such as Scient’X and Biomodex. He has a demonstrated track record or successfully working with the FDA, European and other international regulatory authorities. Mr. Zylber received his M.Sc. in Mechanical Engineering and Manufacturing Systems from Ecole Nationale d’Ingénieurs de Tarbes – ENIT.
About Biom’up
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up develops and commercializes hemostatic products based on patented biopolymers designed to simplify surgeons’ practices for open and minimally invasive surgical procedures across multiple specialties such as cardiac, general, and orthopedic surgery. The Company’s lead product, HEMOBLAST™ Bellows and its laparoscopic applicator are marketed in Europe and the United States.
About HEMOBLAST™
HEMOBLAST™ Bellows is a hemostatic product used to control bleeding in a broad range of open and minimally invasive surgical procedures, including laparoscopy.
Uncontrolled bleeding is a major surgical complication associated with higher mortality, longer hospitalization and higher rates of transfusions and reoperations. Beyond its impact on patient’s health, this major complication causes excess costs in all surgical specialties and is a burden for hospital budgets across the globe. HEMOBLAST™ Bellows is the only surgical hemostatic agent approved by the FDA based on the validated SPOT GRADE™ Surface Bleeding Severity Scale (SBSS), which demonstrates the ability to control a range of bleeding from minimal (oozing), mild (pooling) and moderate (flowing) bleeding. HEMOBLAST™ Bellows is proven to control bleeding with flow rates up to 117 mL per minute. Due to its efficacy, versatility and ease of use, HEMOBLAST™ Bellows is quickly becoming a popular choice amongst U.S. and European surgeons looking for new options to control surgical bleeding challenges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005289/en/
Contact information
Media:
For the United States:
Daniel Yunger
Kekst CNC
+1 212-521-4800
daniel.yunger@kekstcnc.com
For France:
Elvira Pignal
Kekst CNC
+33 6 36 23 68 36
elvira.pignal@kekstcnc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project24.6.2026 17:00:00 EEST | Press release
Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III production capacity and support production of 4 cSt, 6 cSt, and 8 cSt Group III base oils using an existing crude-derived hydrocracked vacuum gas oil stream produced at the Company’s Mobile, Alabama refinery. Combined with the Company’s existing re-refined Group III base oil production, this additional capacity is expected to make Vertex the leading Group III producer in North America. Vertex has completed preliminary design work and has procured a high-pressure lubricants hydrotreating unit. The Company plans to start pr
Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 16:30:00 EEST | Press release
Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insurers is running multiple use cases on Taktile, with projected cost efficiencies of over $90M in claims processing alone. Taktile’s team has a proven
New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 16:25:00 EEST | Press release
A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people navigate uncertainty, recover from setbacks and pursue their goals. At a time when soccer is bringing people and communities together around the world, the findings also highlight how early childhood experiences such as sports, education, and mentorship can help foster resilience and gain confidence from a young age. Key findings across the four countries surveyed include: Confidence drops by 72% when adults consider their ability to recover from setbacks. Respondents were far more lik
StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 16:08:00 EEST | Press release
StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional cell block preparation methods often present challenges in achieving consistent results due to complex procedures, as well as the need for additional equipm
TensorX Launches With €8M Seed Funding Round Led by Darius Cubed Ventures for Bet on European Sovereign AI Infrastructure With Plans to Deploy up to €100M in NVIDIA Blackwell GPUs24.6.2026 16:07:00 EEST | Press release
A team of Irish founders has committed €8 million to Nvidia Blackwell GPUs, including the latest B300 chips, to launch TensorX, a sovereign AI inference platform designed for Europe's AI builders, trusted by regulated industries and already generating revenue from paying customers. The company was founded by Shane Morton, is part of the NVIDIA Inception program and is partnering with Dell on sourcing GPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528791384/en/ (From left to right): Craig Donnelly, Shane Morton, Nicole Morton, Tim Grant At a time when enterprises are racing to adopt artificial intelligence but most remain unwilling to let their data leave European jurisdiction, TensorX offers high-performance inference with zero data retention, running entirely on dedicated hardware in Dublin and Helsinki. TensorX is also in advanced talks around a financing facility to further expand its European footprint,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom